Atogepant for the Preventive Treatment of Migraine

The investigational drug reduced mean migraine days more than placebo.

This double-blind, randomized, controlled trial compared the investigational oral drug atogepant (10 mg, 30 mg, or 60 mg) with placebo in 910 adults with 4 to 14 migraine headaches per month. Patients with >14 headache days per month or with clinically significant coexisting conditions and those who did not respond to more than 4 preventive medications or used opioids or barbiturates on more than 2 days per month were excluded. The study was sponsored by the manufacturer, and atogepant is undergoing FDA review for approval.

Compared with placebo, atogepant resulted in significantly greater reductions in the mean number of migraine days per month across the 12-week study period (−3.7 with 10 mg of atogepant, −3.9 with 30 mg of atogepant, −4.2…

Reviewing Author

Teshamae Monteith, MD

Disclosures

Consultant/Advisory BoardAbbVie; Axsome; Teva; Linpharma; e-Neura; Novartis; Merz; Lundbeck; Axsome; Pfizer. Unpaid co-author for collaborative research sponsored by AbbVie, Pfizer/Biohaven, and Theranica.

RoyaltiesSpringer

Editorial BoardsCephalalgia; Continuum Audio; Neurology Minute; Neurology; American Migraine Foundation; Brain and Life Magazine

Leadership Positions in Professional SocietiesFlorida Society of Neurology (member, Executive Board); American Migraine Foundation (member, Executive Board); United Councils of Neurologic Subspecialities Examination Committee (Vice Chair)

OtherPaid speaking/education for Medscape, Massachusetts Medical Society, American Headache Society, and American Academy of Neurology